We conducted a phase IIa , randomized , double-blind , placebo-controlled , parallel-group study to evaluate the safety and tolerability of dilmapimod , a novel p38 mitogen-activated protein kinase inhibitor , in patients at risk for developing acute respiratory distress syndrome admitted with an Injury Severity Score more than 16 , excluding head trauma .